Jul 26, 2021 09:29AM
Jun 10, 2021 04:19PM
Jun 10, 2021 04:17PM
Apr 1, 2021 08:00AM
Nov 12, 2020 08:00AM
Aug 26, 2020 09:23AM
Aug 3, 2020 08:03AM Tyme Technologies (TYME) Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer
Aug 3, 2020 08:00AM
May 20, 2020 04:05PM
Feb 5, 2020 08:00AM
Feb 5, 2020 08:00AM
Feb 5, 2020 08:00AM
Jan 8, 2020 08:00AM
Jan 8, 2020 08:00AM TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer
Jan 7, 2020 07:25AM
Jan 7, 2020 07:20AM
Nov 4, 2019 04:05PM
Nov 4, 2019 04:05PM
Oct 1, 2019 08:30AM
Sep 30, 2019 08:07AM
Sep 30, 2019 08:00AM TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic
Aug 8, 2019 08:00AM
Aug 8, 2019 08:00AM
Jul 8, 2019 08:00AM
Jul 5, 2019 09:29AM
Jul 5, 2019 08:02AM
Jul 5, 2019 08:00AM
May 29, 2019 09:09AM TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results
May 29, 2019 09:09AM
May 29, 2019 07:30AM
May 29, 2019 07:30AM
Feb 25, 2019 08:02AM
Feb 25, 2019 08:00AM
Feb 25, 2019 08:00AM
Feb 14, 2019 08:08AM Tyme Inc. (TYME) Reports Encouraging Prelim. SM-88 Clinical Results in Phase II Study of Patients with Biomarker Recurrent Prostate Cancer
Feb 14, 2019 08:00AM
Feb 14, 2019 08:00AM
Feb 11, 2019 07:38AM
Feb 11, 2019 07:30AM
Feb 11, 2019 07:30AM
Jan 18, 2019 09:31AM
Oct 10, 2018 06:04AM Tyme Inc. (TYME) Reports Inclusion of SM-88 in PanCAN’s 'Precision Promise' Adaptive Phase II/III Pancreatic Cancer Trial Platform
Oct 10, 2018 06:00AM
Oct 10, 2018 06:00AM
Sep 18, 2018 08:04AM
Sep 18, 2018 08:00AM
Sep 18, 2018 08:00AM
Mar 14, 2018 09:22AM
Mar 14, 2018 08:04AM Tyme Inc. (TYME) Reports FDA Acceptance of IND to Begin Phase II Trial in Pancreatic Cancer
Mar 14, 2018 08:00AM

322,898 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All